Bacitracin: A Literature Course on What the Published Studies Report

Bacitracin is one of the oldest peptide antibiotics still in clinical and agricultural use, and the literature on it spans fermentation science, materials engineering, veterinary nutrition, microbiology and case reports. This course walks through that literature module by module. It does not recommend any use, dose or protocol. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medicine or a medical condition.

Module 1: What Bacitracin Is and How It Has Been Studied

Bacitracin is not a single molecule but a mixture of closely related cyclic polypeptides produced by strains of Bacillus. Because it is a non-ribosomally assembled peptide, much of the older and newer literature on bacitracin is microbiological and biotechnological rather than clinical: researchers have studied how to isolate the producing organism, how to raise fermentation yield, and how to formulate the resulting peptide.

One methods paper described the isolation, purification and identification of bacitracin-producing Bacillus licheniformis from fresh feces of healthy pigs, presenting a visualised protocol for recovering and confirming the producing strain (PMID 38884462). On the production side, a metabolic-engineering study reported that enhancing NADPH generation by overexpressing the glucose-6-phosphate dehydrogenase gene zwf in Bacillus licheniformis increased bacitracin production (PMID 30267286). Together these papers frame bacitracin as a fermentation product whose supply and purity are themselves research questions.

Forms that appear in the cited literature

• Topical semi-solid formulations — a formulation study developed and characterised a chitosan-decorated cream containing bacitracin for topical delivery and tested its antibacterial activity in vitro (PMID 36139931).
• Device and implant coatings — one study immobilised bacitracin on titanium and evaluated the coated surfaces in vivo (PMID 27914255).
• Soaked surgical materials — a surgical research paper compared antimicrobial activity between bacitracin-soaked sutures and a triclosan-coated suture (PMID 34700295).
• Surgical irrigation — a pharmacy case report described bacitracin used as an intraoperative irrigation solution (PMID 21289327).
• Feed-grade antibacterial — an animal nutrition study fed an antibacterial bacitracin to nursery pigs challenged with F18⁺ Escherichia coli (PMID 37237906).
• Labelled research probe — a medicinal chemistry paper synthesised fluorescein-labelled bacitracin and daptomycin conjugates and used them for fluorescence imaging and evaluation (PMID 27026529).

Limits of the evidence in Module 1

The papers above define bacitracin operationally — as a fermentation product, a cream ingredient, a coating, a feed additive or a labelled probe — but none of them is a modern head-to-head clinical trial of bacitracin in humans. Strain-level and formulation-level differences mean that results obtained with one preparation do not automatically describe another, and the cited set contains no standardisation study comparing commercial bacitracin preparations against each other.

Module 2: Mechanism as Described in the Literature

Across the cited papers, bacitracin is treated as a cell-envelope-active peptide: its antibacterial effect is discussed in the context of bacterial cell-wall synthesis and of envelope stress-response systems, rather than as an intracellular or ribosomal inhibitor. The most direct mechanistic material in the verified set concerns how bacteria defend themselves against it and how that defence can be manipulated.

A 2025 antimicrobial pharmacology paper examined the nature of bacitracin resistance in Staphylococcus aureus, investigating the determinants that allow the organism to tolerate the peptide (PMID 41186227). Complementing that, researchers reported that colistin induced S. aureus susceptibility to bacitracin, indicating that envelope-directed agents can alter how the organism responds to the peptide (PMID 30515145). In a different pathogen, the study of the high-level ceftriaxone-resistant gonococcal FC428 clone reported that bacitracin enhanced ceftriaxone susceptibility, an interaction consistent with cell-wall-level activity (PMID 37982635).

Mechanism has also been probed with chemical tools. The fluorescein-labelled bacitracin conjugate work was undertaken specifically so that the peptide's interaction with bacterial targets could be visualised by fluorescence imaging (PMID 27026529).

Limits of the evidence in Module 2

Mechanistic conclusions in this set are drawn from bacterial systems, not from mammalian physiology, and the interaction studies were performed in vitro with defined strains. Synergy or susceptibility-enhancing effects observed against one clone or one species cannot be generalised to other organisms, to mixed infections, or to any human treatment setting. None of the cited papers established a dose–response relationship in humans.

Module 3: Reported Outcomes by Study

The table below summarises the model, the setting and the reported direction of findings for each experimental paper in the verified set. No paper in this set promises a clinical benefit, and several were explicitly comparative or exploratory.

How to read these outcomes

Three distinct research questions are mixed together in this literature. The first is delivery: can bacitracin be held in a cream, on a suture or on a metal surface and still act against bacteria, as examined in the cream, suture and titanium studies (PMID 36139931, PMID 34700295, PMID 27914255). The second is combination pharmacology: can bacitracin change how another antibiotic performs, as reported in the gonococcal and staphylococcal susceptibility studies (PMID 37982635, PMID 30515145). The third is animal gut health, as in the nursery pig challenge study (PMID 37237906).

Limits of the evidence in Module 3

Most of these designs are in vitro or animal studies with small numbers of organisms, surfaces or animals, short observation periods and laboratory-defined endpoints. Antimicrobial activity measured on an agar plate or a suture segment is not a measure of infection prevention in people; bone and implant findings in an animal model are not device approval data; and pig performance and intestinal endpoints do not transfer to human gastrointestinal disease. None of these studies reported human clinical outcomes such as wound healing rates, infection incidence or survival.

Module 4: Bacitracin Side Effects: What Studies Report

Two categories of adverse outcome appear in the verified literature: an immediate hypersensitivity event in a human surgical setting, and the microbiological adverse outcome of resistance selection.

Hypersensitivity reported in a human case

A health-system pharmacy report described intraoperative anaphylaxis associated with bacitracin irrigation, documenting a severe immediate reaction in the operative setting rather than a mild local effect (PMID 21289327). This is a single published case, which is the weakest study design for estimating how often an event occurs, but it is the kind of report that anchors the known concern about bacitracin hypersensitivity when the peptide contacts large surfaces or open tissue.

Resistance as a reported adverse outcome

Researchers reported that bacitracin-resistant Staphylococcus aureus was induced in the chicken gut and in vitro under bacitracin exposure, meaning resistant organisms emerged during exposure in both settings (PMID 38685360). A subsequent paper examined the nature of bacitracin resistance in S. aureus, characterising how that resistance is established (PMID 41186227). Read together, the two papers describe selection pressure as a documented consequence of exposure — an outcome that matters at population and agricultural level rather than as a symptom in an individual.

Limits of the evidence in Module 4

The verified set contains no controlled safety trial, no incidence rate for allergic contact dermatitis or anaphylaxis, no nephrotoxicity dataset and no pediatric or pregnancy safety data for bacitracin. A single case report cannot establish frequency, causality beyond the individual case, or risk factors; the resistance work was performed in poultry and laboratory systems, not in treated humans. Absence of a reported adverse event in this small set is not evidence that the event does not occur.

Module 5: Pharmacokinetics Where Data Exist

The verified literature for this course contains no human pharmacokinetic study of bacitracin — no plasma concentration–time curves, no half-life, no clearance, no bioavailability figure. What it contains instead are surrogate measures of where the peptide goes and how it is released from a carrier.

The topical formulation paper carried out in vitro characterisation of a chitosan-decorated bacitracin cream alongside its antibacterial testing, which is the kind of physicochemical work that precedes any permeation or delivery claim (PMID 36139931). The implant work immobilised bacitracin on titanium so that the peptide remained associated with the surface, and the study evaluated that surface in vivo (PMID 27914255). The suture comparison assessed antimicrobial activity from bacitracin-soaked material, which is an activity endpoint rather than a release-kinetics endpoint (PMID 34700295). For localisation, the fluorescein-labelled bacitracin conjugates were synthesised and evaluated by fluorescence imaging, giving a visual rather than quantitative account of peptide distribution at the bacterial level (PMID 27026529).

Limits of the evidence in Module 5

Formulation characterisation, surface immobilisation and fluorescence imaging are not pharmacokinetics. None of the cited papers reported absorption through intact or injured human skin, systemic exposure after irrigation, tissue distribution in humans, metabolism, or renal handling. Any statement about systemic bacitracin exposure would therefore go beyond the verified set, and this course does not make one.

Module 6: Regulatory Status, Stated Factually

Bacitracin's regulatory position differs sharply by route and by jurisdiction, and the distinction matters for how the literature should be read.

• Topical and ophthalmic products. In the United States, bacitracin has a long history as an approved topical antibacterial, including over-the-counter first-aid ointments (alone or combined with other antibacterials) and prescription ophthalmic ointment. These are finished, labelled drug products regulated as such.
• Injectable bacitracin. The intramuscular formulation was withdrawn from the United States market after the U.S. Food and Drug Administration requested that manufacturers voluntarily withdraw bacitracin for injection in 2020. There is no approved systemic bacitracin product in the United States today.
• Irrigation and surgical use. Bacitracin irrigation described in the surgical literature, including the case of intraoperative anaphylaxis associated with bacitracin irrigation (PMID 21289327), reflects practitioner-prepared or institutional use rather than an approved irrigation indication.
• Veterinary and feed use. Bacitracin salts are used in animal agriculture under veterinary regulations, which is the context for the study feeding an antibacterial bacitracin to nursery pigs (PMID 37237906) and for the poultry-gut resistance work (PMID 38685360).
• Research-use-only material. Bacitracin is also sold as a laboratory reagent — for susceptibility testing, selective media and chemistry work such as the labelled conjugate synthesis (PMID 27026529). Research-use-only material is not manufactured, labelled or released as a medicine.
• Compounding. Compounded preparations are made by licensed pharmacies under compounding law for an identified patient need; compounded products are not FDA-approved drugs and are not reviewed for safety, efficacy or manufacturing quality in the way approved products are.

Regulatory descriptions above are general factual background and not legal advice; rules differ by country and by state and change over time.

Limits of the evidence in Module 6

Approval status says nothing about how well a compound performs in any specific situation, and the presence of an approved topical product does not validate the experimental uses — implant coatings, sutures, irrigation, combination antibiotic regimens — described in the research literature. Conversely, the withdrawal of an injectable product is a regulatory action whose reasoning is not contained in any of the papers cited here.

What the Studies Did Not Test

The verified literature for this course did not include:

1. Randomised human trials of bacitracin for wound infection prevention, surgical site infection, or any other clinical endpoint.
2. Human pharmacokinetics of any route — no half-life, exposure, distribution or elimination data appear in the cited papers.
3. Dose-ranging work in humans. No paper in this set reported a human dose, concentration or schedule, so none is stated on this page.
4. Long-term safety surveillance, incidence estimates for hypersensitivity, or renal safety datasets.
5. Comparative effectiveness against modern topical or systemic antibiotics in patients; the suture study was a laboratory comparison of antimicrobial activity (PMID 34700295), not a clinical trial.
6. Translation of combination findings — the reported enhancement of ceftriaxone susceptibility in the gonococcal FC428 clone (PMID 37982635) and the colistin-induced bacitracin susceptibility in S. aureus (PMID 30515145) were in vitro observations only.
7. Human resistance consequences of exposure; resistance emergence was documented in chicken gut and in vitro systems (PMID 38685360) and characterised mechanistically in S. aureus (PMID 41186227).

Readers comparing this literature should note how narrow each study's question was, and that a laboratory or livestock result is a hypothesis about humans rather than an answer. Again, this page is educational only and is not medical advice.

References

• Formulation, In Vitro Characterization and Antibacterial Activity of Chitosan-Decorated Cream Containing Bacitracin for Topical Delivery (Antibiotics, 2022)
• Bacitracin-resistant Staphylococcus aureus induced in chicken gut and in vitro under bacitracin exposure (Microbial Pathogenesis, 2024)
• Immobilizing bacitracin on titanium for prophylaxis of infections and for improving osteoinductivity: An in vivo study (Colloids and Surfaces B: Biointerfaces, 2017)
• Bacitracin enhances ceftriaxone susceptibility of the high-level ceftriaxone-resistant gonococcal FC428 clone (Microbiology Spectrum, 2023)
• Intestinal Damages by F18(+)Escherichia coli and Its Amelioration with an Antibacterial Bacitracin Fed to Nursery Pigs (Antioxidants, 2023)
• Enhancement of Bacitracin Production by NADPH Generation via Overexpressing Glucose-6-Phosphate Dehydrogenase Zwf in Bacillus licheniformis (Applied Biochemistry and Biotechnology, 2019)
• Nature of bacitracin resistance in Staphylococcus aureus (Antimicrobial Agents and Chemotherapy, 2025)
• Fluorescein-labeled Bacitracin and Daptomycin Conjugates: Synthesis, Fluorescence Imaging and Evaluation (Medicinal Chemistry, 2016)
• Isolation, Purification, and Identification of Bacitracin-producing Bacillus licheniformis from Fresh Feces of Healthy Pigs (JoVE, 2024)
• Intraoperative anaphylaxis associated with bacitracin irrigation (American Journal of Health-System Pharmacy, 2011)
• Comparison of Antimicrobial Activity Between Bacitracin-Soaked Sutures and Triclosan Coated Suture (Journal of Surgical Research, 2022)
• Colistin Induces S. aureus Susceptibility to Bacitracin (Frontiers in Microbiology, 2018)